Perflow Medical’s Cascade17 Dynamic Nonocclusive Remodeling Net Launched in Europe

March 10, 2021—Perflow Medical, an Israel-based developer of neurovascular devices, announced the launch of the Cascade17 nonocclusive remodeling net in Europe. The neurovascular device is designed for the support of distal and tortuous vessel anatomy during coil embolization of intracranial aneurysms of smaller vessels.

The Cascade17 is based on Perflow Medical’s Cerebral Net platform, which includes the Stream dynamic neurothrombectomy net (Stream Net).

According to the company, early clinical experience with the Cascade17 is promising and further expands the range of brain vessels that can now be treated with Perflow’s Cerebral Net technology. The nonocclusive net design enables continuous blood flow during cerebral aneurysm repair and coiling, which maintains appropriate perfusion and may improve patient outcomes.

Xavier Barreau, MD, Senior Interventional Neuroradiologist at Centre Hospitalier Universitaire de Bordeaux, Neuroradiology Unit in Bordeaux, France, was the first physician to use the Cascade17 clinically.

“The ability to perform Cascade-supported aneurysm coiling without the need to use an occlusive balloon or to place a stent in patients with brain aneurysms provides clinicians with a unique opportunity to safely position embolic coils in challenging situations and deliver a successful treatment without putting patients on lifelong medication,” commented Dr. Barreau in the company’s press release. “After a series of successful treatments with the Cascade Agile, we recently began using the Cascade17 to treat aneurysms in smaller vessels where access through a thinner microcatheter is preferred. The Cascade17 could easily be navigated to the distal anatomy, and the radiopaque braid structure provided excellent coil support. We look forward to continue using this unique device in our routine practice.”

The Cascade Net and Stream Net product families are commercially available across Europe for the treatment of intracranial aneurysms and acute ischemic stroke, respectively. Perflow products are not yet approved for clinical use within the United States, advised the company.